

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PC30246J
Submission of Missing Parts For Appln. No. 10/723,140



Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to:
Mail Stop: Missing Parts, Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 22nd day of April 2004.

s/


Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
JOHAN WILHELM STJERNCHANTZ, et al.

Serial No.: 10/723,140

Confirmation No.: 9449

Filed: November 25, 2003

For: **PROSTAGLANDIN DERIVATIVES FOR
THE TREATMENT OF GLAUCOMA OR
OCULAR HYPERTENSION**

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Mail Stop: Missing Parts
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF MISSING PARTS

Sir:


In response to the Notice To File Missing Parts Of Application (Filed Under 37 CFR §1.53(b)) dated March 11, 2004, in the above-identified application, Applicant submits herewith all missing parts, namely, a signed Declaration in accordance with 37 CFR §1.63. A copy of the Notice To File Missing Parts of Nonprovisional Application is enclosed.

A signed Declaration was previously submitted with the application filed on November 25, 2003. Please carefully review the enclosed copy of the Declaration for the inventors' signatures.

Applicants do not believe the \$130.00 fee is necessary. However, to expedite the allowance of the application, please charge \$130.00, the fee set forth in 37 CFR §1.16(e), to Deposit Account No. 500329. (A duplicate of this sheet is enclosed.) If any other fees are due in connection with the filing of this response, including any fee for a required extension of time under 37 CFR 1.136(a), for which Applicant hereby petitions, please charge all necessary fees to the deposit account.

Respectfully submitted,

Date: April 22, 2004


Joseph F. Reidy
Attorney For Applicants
Registration No. 39,340

Pfizer Inc.
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7320
Fax: (858) 678-8233